A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety

Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana Patterson, Jill Samis, Paola Aimone, Alex Allepuz, Ksenia Titorenko, Darintr Sosothikul

Open source

DOI: 10.1182/bloodadvances.2020003759
Published: 2021-07-26
Container: Blood Advances
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2020003759,
  title = {A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety},
  author = {Nobuko Hijiya and Alexey Maschan and Carmelo Rizzari and Hiroyuki Shimada and Carlo Dufour and Hiroaki Goto and Hyoung Jin Kang and Terri Guinipero and Zeynep Karakas and Francisco Bautista and Stéphane Ducassou and Keon Hee Yoo and Christian Michel Zwaan and Frédéric Millot and Briana Patterson and Jill Samis and Paola Aimone and Alex Allepuz and Ksenia Titorenko and Darintr Sosothikul},
  year = {2021},
  journal = {Blood Advances},
  doi = {10.1182/bloodadvances.2020003759},
  url = {https://doi.org/10.1182/bloodadvances.2020003759}
}

RIS

TY  - JOUR
TI  - A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety
AU  - Nobuko Hijiya
AU  - Alexey Maschan
AU  - Carmelo Rizzari
AU  - Hiroyuki Shimada
AU  - Carlo Dufour
AU  - Hiroaki Goto
AU  - Hyoung Jin Kang
AU  - Terri Guinipero
AU  - Zeynep Karakas
AU  - Francisco Bautista
AU  - Stéphane Ducassou
AU  - Keon Hee Yoo
AU  - Christian Michel Zwaan
AU  - Frédéric Millot
AU  - Briana Patterson
AU  - Jill Samis
AU  - Paola Aimone
AU  - Alex Allepuz
AU  - Ksenia Titorenko
AU  - Darintr Sosothikul
PY  - 2021
JO  - Blood Advances
DO  - 10.1182/bloodadvances.2020003759
UR  - https://doi.org/10.1182/bloodadvances.2020003759
ER  -

APA

Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., Kang, H. J., Guinipero, T., Karakas, Z., Bautista, F., Ducassou, S., Yoo, K. H., Zwaan, C. M., Millot, F., Patterson, B., Samis, J., Aimone, P., Allepuz, A., Titorenko, K., & Sosothikul, D. (2021). A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Advances. https://doi.org/10.1182/bloodadvances.2020003759

Source records

crossref · retrieved 2026-09-25T10:52:56.375Z